Novel Strategies for IBS-C

Goal Statement

This activity has been designed to meet the educational needs of gastroenterologists, physician assistants, and nurse practitioners involved in the diagnosis and management of IBS-C.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Describe recent advances in understanding the pathophysiology of IBS-C

Explain the contribution of methane and methanogens to the pathogenesis of IBS-C

Discuss the latest evidence regarding novel strategies for IBS-C

Credit Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and the Gastrointestinal Health Foundation.

The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Release Date: July 18, 2016
Expiration Date: July 18, 2017   
*This program has expired. CME credit is no longer available.

Faculty Disclosure Statement

Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

Speaker/ Planning Committee Members Disclosures
In accordance with the ACCME Standards for Commercial Support of CME, the speaker for this course have been asked to disclose to participants the existence of any financial interest and/or relationship(s) (e.g., paid speaker, employee, paid consultant on a board and/or committee for a commercial company) that would potentially affect the objectivity of his/her presentation or whose products or services may be mentioned during their presentation. The following disclosures were made:

Planning Committee Member
Julie Messick (writer) -No Relevant Relationships
Rick Ricer, MD; compliance reviewer -No Relevant Relationships
Susan Tyler -No Relevant Relationships
Barbara Forney -No Relevant Relationships

Course Director/Speaker
Mark Pimentel, MD -Investigator, advisory board and consultant – Synthetic Biologics, Commonwealth Labs, Salix/Valeant Pharmaceuticals, Naia Pharmaceuticals and QOL Medical

Learner Assurance Statement

The University of Cincinnati is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s). The University of Cincinnati is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.